News Releases

December 18, 2019
DURHAM, NC – December 18, 2019 – Beginning January 1, 2020 Bioventus , a global leader in orthobiologic solutions, has secured preferred access for Blue Cross Blue Shield of Michigan Medicare Advantage and Commercial patients to DUROLANE , GELSYN-3 and SUPARTZ FX to treat knee osteoarthritis (OA)
October 10, 2019
DURHAM, NC – October 10, 2019 – In support of World Arthritis Day, which is celebrated every October 12 to raise awareness of arthritis, Bioventus , a global leader in orthobiologics, has launched a disease and product information website called OAKneePainRelief.com which combines information on
March 27, 2019
DURHAM, NC – March 27, 2019 – Bioventus , a global leader in orthobiologic solutions, is launching OSTEO AMP SELECT Fibers , an innovative addition to its allograft line of OSTEOAMP bone graft substitutes for spine, foot & ankle, orthopaedic, and trauma surgeons.
January 29, 2019
HOOFDDORP, THE NETHERLANDS – January 29, 2019 – Bioventus , a global leader in orthobiologic solutions, is launching DUROLANE , its single-injection joint-fluid osteoarthritis (OA) treatment, in Malaysia and has selected Athrotech as its exclusive distribution partner for the market.
January 15, 2019
DURHAM, NC – January 15, 2019 – Bioventus , a global leader in orthobiologic solutions, is launching OSTEOMATRIX+, its next generation biphasic bone graft for use in bone remodeling in a variety of orthopaedic and spine applications. OSTEOMATRIX+ is a moldable bone graft substitute consisting of
October 25, 2018
DURHAM, NC – October 25, 2018 – Bioventus , a global leader in orthobiologic solutions, today announced the appointment of Susan M. Stalnecker, former Vice President and Treasurer, E.I. du Pont de Nemours and Company, to the company’s Board of Managers, replacing Michael Minogue.
Displaying 51 - 60 of 67